CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Lowered by BidaskClub

BidaskClub downgraded shares of CytomX Therapeutics (NASDAQ:CTMX) from a buy rating to a hold rating in a report issued on Thursday, December 7th.

CTMX has been the subject of several other research reports. Wedbush began coverage on CytomX Therapeutics in a report on Thursday, September 7th. They issued an outperform rating and a $26.00 price target for the company. Zacks Investment Research cut CytomX Therapeutics from a buy rating to a hold rating in a report on Friday, November 10th. Oppenheimer restated a hold rating on shares of CytomX Therapeutics in a report on Wednesday, October 4th. Jefferies Group set a $25.00 price target on CytomX Therapeutics and gave the company a buy rating in a report on Friday, August 25th. Finally, Bank of America lifted their price target on CytomX Therapeutics from $30.00 to $34.00 and gave the company a buy rating in a report on Wednesday, October 4th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company. The company has an average rating of Hold and a consensus target price of $31.88.

CytomX Therapeutics (NASDAQ:CTMX) traded down $0.96 on Thursday, reaching $21.11. The company’s stock had a trading volume of 268,937 shares, compared to its average volume of 384,989. The stock has a market cap of $847.68, a PE ratio of -13.28 and a beta of 0.47. CytomX Therapeutics has a 52 week low of $10.40 and a 52 week high of $24.67.

In other news, CFO Debanjan Ray sold 2,500 shares of CytomX Therapeutics stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $18.10, for a total value of $45,250.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Robert I. Tepper sold 24,777 shares of CytomX Therapeutics stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $24.34, for a total value of $603,072.18. The disclosure for this sale can be found here. Insiders sold a total of 153,009 shares of company stock worth $3,500,367 over the last ninety days. Corporate insiders own 4.70% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc lifted its position in CytomX Therapeutics by 28.6% during the 2nd quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 1,434 shares in the last quarter. Macquarie Group Ltd. acquired a new position in CytomX Therapeutics during the 3rd quarter worth approximately $107,000. Cubist Systematic Strategies LLC acquired a new position in CytomX Therapeutics during the 2nd quarter worth approximately $174,000. Goldman Sachs Group Inc. acquired a new position in CytomX Therapeutics during the 1st quarter worth approximately $190,000. Finally, Voya Investment Management LLC acquired a new position in CytomX Therapeutics during the 2nd quarter worth approximately $203,000. 63.13% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Lowered by BidaskClub” was first published by Week Herald and is the property of of Week Herald. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://weekherald.com/2017/12/30/cytomx-therapeutics-ctmx-cut-to-hold-at-bidaskclub.html.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply